CEPI

A new early-stage trial assessing @UniofOxford's Bundibugyo ebolavirus vaccine candidate has launched in Uganda.

The CEPI-funded study is being conducted by @MRC_Uganda with the @OxfordVacGroup and @PSIOxford and @SerumInstIndia manufacturing doses: lshtm.ac.uk/research/units…

SFTS, or Severe Fever with Thrombocytopenia Syndrome, is a tick-borne virus that kills around one in ten people diagnosed with it in Japan. In 2025, cases reached record highs – and there's no vaccine to protect against it.

In Nagasaki, scientists supported by CEPI are exploring whether a new type of mRNA vaccine designed with artificial intelligence and delivered in an innovative protective coating, known as a ‘nanaoball’, could change that, and at the same time help the world respond faster to the next Disease X.

Read our latest Impact Story to hear more about the project, direct from the researchers: cepi.net/innovations-fo…

New speakers announced for CEPI's World Health Summit panel discussion, From Crisis Response to Resilience: Innovating for Health Security Beyond Borders.

Additional panellists include:

🔵 Dr. Florika Fink-Hooijer, Director General, EC HERA
🔵 Salina Grenet Catalano, Ministry for Europe and Foreign Affairs, Director of Global Affairs, France
🔵 Prof. Dr. Muyembe Jean-Jacques, DG of Institut National de Recherche Biomedicale
🔵 Prof. Dr Charlotte Watts, Executive Director of Solutions, Wellcome Trust

Echoing the World Health Summit 2026 theme, “From Crisis to Resilience: Innovating for Health”, this session will position CEPI 3.0 as a practical framework connecting technological innovation, cross-sector and cross-border partnership, and population-level resilience – and explore how investment in CEPI 3.0 helps countries mitigate the health, socio-economic and security impact of outbreaks.

Date: Monday, 12th October; Time: 16:00-17:30 CEST
Attend in person or watch the livestream. Register now: worldhealthsummit.org/sessions/0342e…

CEPI's September newsletter is now available! 🗞️

This month spotlights continued momentum for CEPI 3.0, with $240 million in new funding pledged by partners at UNGA 81. It also features our latest R&D partnerships, new funding opportunities and lots more.
linkedin.com/pulse/partners…

As global health leaders ready themselves for this year’s @WorldHealthSmt Health Summit in Berlin, CEPI invites you to join its official panel discussion, From Crisis Response to Resilience: Innovating for Health Security Beyond Borders.

Register: worldhealthsummit.org/sessions/0342e…

New funding: The @BioPrevail x CEPI Biosecurity Innovation Challenge is seeking practical biosafety and biosecurity innovations to strengthen vaccine R&D and manufacturing during epidemic and pandemic responses, supporting CEPI’s 100 Days Mission: bioprevail.org/challenge/biop…

Check out this new blog to discover how CEPI has partnered with @AnthropicAI to help accelerate critical steps in the response to the devastating Bundibugyo ebolavirus outbreak affecting the DRC ⬇️

We're delighted to welcome CAD$5 million in new, targeted funding from the Government of Canada to support CEPI's biosecurity programme.

This funding continues Canada’s leadership in implementing CEPI's biosecurity strategy, ensuring the life-saving research we fund is conducted to the highest standards of safety and security.

We look forward to continuing our partnership with Canada to strengthen global health security — and to secure the future, for everyone.

Read more about CEPI’s biosecurity strategy: cepi.net/biosecurity
Read the full announcement: pm.gc.ca/en/news/backgr…

@GAC_Corporate

🔉 Major new funding for CEPI announced today.

Ethiopia, Norway and the UK have pledged a combined US$240 million to support CEPI’s five-year plan to transform the world’s ability to prevent and respond to future epidemic and pandemic threats ➡️ cepi.net/ethiopia-norwa…

Beginning shortly CEPI's flagship UNGA 81 side-event: Building Crisis-Ready Coalitions: From Fragmentation to Readiness.

Join virtually with the livestream link➡️ us02web.zoom.us/j/88468178446?…

CEPI is pleased to announce Dr @SaniaNishtar CEO of @gavi, will also join CEPI's flagship UNGA 81 side-event: Building Crisis-Ready Coalitions: From Fragmentation to Readiness.

Dr Nishtar joins a panel of leading voices from governments, global health and philanthropy to talk about how long-term partnerships can help turn fragmented pandemic preparedness efforts into stronger collective readiness, and what we can learn from real-world responses such as the Bundibugyo outbreak.

📍 New York; 21 September | 11:30 ET (17:30 CEST)

Join us in person or online.

➡️ Register: web-eur.cvent.com/event/44c8f5cf…

Speaker announcement for CEPI's UNGA 81 side-event ⬇️

We’re pleased to announce the following speakers will be joining CEPI’s flagship side event at UNGA, Building Crisis-Ready Coalitions: From Fragmentation to Readiness:

🔵 H.E. Dr Mekdes Daba Feyssa, Minister of Health, Ethiopia
🔵 State Secretary Andreas Motzfeldt Kravik, Norwegian Ministry of Foreign Affairs
🔵 Minister Chris Elmore MP, Parliamentary Under-Secretary of State, FCDO
🔵 Dr Chikwe Ihekweazu, Executive Director, WHO Health Emergencies Programme
🔵 Dr Ciro Ugarte, Director, Health Emergencies, PAHO
🔵 Dr Paulin Basinga, Director, Africa, Gates Foundation
🔵 Hon. Prof Jane Halton, Chair, CEPI Board
🔵 Dr Richard Hatchett, CEO, CEPI

The discussion will explore how long-term partnerships can transform fragmented efforts into collective readiness for the 100 Days Mission, drawing on real-world progress, including the rapid response to the Bundibugyo outbreak.

📍 Japan Society, New York | 21 September, 11:30 ET (17:30 CEST)

Attend in person or watch the livestream.

Register now: web-eur.cvent.com/event/44c8f5cf…

Good decisions in an outbreak depend on good evidence.

That’s why CEPI is investing US$3.9 million in three research projects to strengthen understanding of the Bundibugyo ebolavirus (BDBV) outbreak in the Democratic Republic of the Congo (DRC), helping guide the response and support clinical trials of BDBV vaccine candidates ⬇️

cepi.net/new-research-s…

Today we announced new funding of up to US$8.9 million in @Immunoscript to advance clinical testing of its thermostable next-generation self-amplifying RNA vaccine technology.

Discover more:
cepi.net/india-ramps-di…

This week we hosted a landmark pandemic simulation exercise with Indonesia's Ministry of Health @KemenkesRI to strengthen national and regional readiness against a future ‘Disease X’.

“If we know that a threat can kill millions or even billions of our brothers and sisters, then we must be prepared for it" - @BudiGSadikin
cepi.net/indonesia-step…

It is with great sadness that CEPI received the news that Dr Vaseeharan Sathiyamoorthy, or Vasee Moorthy for short, passed away suddenly on 30 August 2026. He was the Strategy and Scientific Adviser in the Department of Science for Health and acting Lead of the R&D Blueprint for Epidemics in the Office of the Chief Scientist at WHO.

CEPI’s Deputy CEO, Aurélia Nguyen, had the privilege of spending the past week with Vasee in the Democratic Republic of the Congo, as part of the WHO delegation led by Dr Chikwe Ihekweazu, observing the Ebola outbreak response and working together to advance preparations for vaccine clinical trials. It was a week of long days - airports, offices, bumpy roads, hours in the field - which provided an opportunity to talk at length about the work and the people behind it.

Vasee was one of the most respected figures in the global research community. He was especially proud of his work designing the Phase 3 clinical trial for the malaria vaccine that ultimately secured licensure. Over seventeen years at WHO, he valued deeply that it was an institution where scientific advice could be given honestly and taken seriously. He spoke warmly of the wide community of researchers he convened and consulted throughout his career, and of how much he enjoyed that collaborative spirit.

During the visit to Kinshasa and Bunia, Vasee’s overarching drive was to ensure the country had ownership of the research component of the response, in the two clinical trials for therapeutics under way and in the preparation for the vaccine clinical trials. Having clinical trial research capacity in lower-income countries was the theme that animated him through his whole career, whether for endemic diseases like malaria or in outbreak response for Ebola.

Outside of work, Vasee was a passionate hiker who organised a weekly hiking group and chased a personal goal of doing a thousand metres of elevation every week. He was looking forward to the multi-day hike he took every September. He was also a loving husband and devoted father to his three children and spoke of his family often and with real pride.

Vasee brought rigour, warmth, and an unmistakable enthusiasm to everything he did - for science, in the mountains, and for the people around him. This is deeply shocking and tragic news, he will be deeply missed by the many communities he was part of. Our thoughts are with his family at this time.

CEPI's August newsletter is now available ⬇️

This edition spotlights CEPI’s ongoing efforts to close the mpox vaccine access gap, the latest progress in the fight against Bundibugyo ebolavirus—including funding for a fifth vaccine candidate and the initiation of another Phase 1 trial—plus all the latest R&D news and our other regular features.

linkedin.com/pulse/closing-…

We've announced a new US$16.5 million partnership with African biopharmaceutical company Minapharm Group to develop their Bundibugyo vaccine candidate.

The Bundibugyo epidemic in the DRC is the fastest-growing and second-largest Ebola outbreak on record: cepi.net/african-bundib…

100 days into the Bundibugyo emergency, the global health response has moved at a pace unimaginable a decade ago. Yet the outbreak is far from contained. It's painful proof that in a deadly epidemic, even faster than ever is often not fast enough.

➡️ Read more on our website: cepi.net/100-days-bundi…

Do existing vaccines against Zaire ebolavirus generate immune responses to Bundibugyo ebolavirus?

CEPI is investing US$4.17 million in four research projects to help answer this pressing question. The projects will test whether existing Ebola vaccines, including Ervebo, can generate immune responses against Bundibugyo ebolavirus, the virus behind the escalating outbreak in DRC. First results expected within months.

Read more: cepi.net/new-studies-te…